Product news

Share this article:

Novo Nordisk discontinued its experimental AERx inhaler and took a charge of $260 million in 2007, saying the product offered little clinical benefit. “Pfizer's decision on Exubera prompted this,” Mads Krogsgaard Thomsen, Novo's chief scientific officer, in  said in a published report. “We have realized that the trend is for physicians to start treatment with something simple rather than a device that has to be loaded with insulin for each mealtime use.” A Novo spokeswoman said that a “significant number'” of 360 jobs at the company's Hayward, California site will be “affected.”

Three Rivers Pharmaceutical has finalized acquisition of the hepatitis C drug Infergen from Valeant Pharmaceuticals International. Valeant is receiving $91 million from Three Rivers for the procurement.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.